A hybrid phase I-II/III clinical trial design allowing dose re-optimization in phase III

DOI10.1111/BIOM.12994MaRDI QIDQ5214489zbMATH OpenOpenAlexWikidataFDO

Authors Andrew G. Chapple, Peter F. Thall

Publication date 7 February 2020

Published in Biometrics (Search for Journal in Brave)

Full work available at URL http://europepmc.org/articles/pmc6486466

zbMATH Keywords

Bayesian designclinical trialdose findingphase I-II clinical trialphase III clinical trial

Mathematics Subject Classification ID

Statistical block designs (62K10) Applications of statistics to biology and medical sciences; meta analysis (62P10)

Recommendations

• A three-stage Bayesian adaptive phase I/II design and simulation studies
• A hybrid geometric phase II/III clinical trial design based on treatment failure time and toxicity
• Bayesian designs for phase I--II clinical trials
• Bayesian phase I/II adaptively randomized oncology trials with combined drugs
• A Bayesian seamless phase I–II trial design with two stages for cancer clinical trials with drug combinations

Cited in

(6)

• Making Efficient Use of Patients in Designing Phase III Trials Investigating Simultaneously a Set of Targeted Therapies with Different Targets
• A three-stage Bayesian adaptive phase I/II design and simulation studies
• A novel Bayesian continuous piecewise linear log-hazard model, with estimation and inference via reversible jump Markov chain Monte Carlo
• A phase I--II design based on periodic and continuous monitoring of disease status and the times to toxicity and death
• A hybrid geometric phase II/III clinical trial design based on treatment failure time and toxicity
• Bayesian analysis of Cox-type regression model with partly linear covariate effects via reversible jump Markov chain Monte Carlo

This page was built for publication: A hybrid phase I-II/III clinical trial design allowing dose re-optimization in phase III

Report a bug (only for logged in users!)Click here to report a bug for this page (MaRDI item Q5214489)